Mayo Clinic Clival Chordoma Case Series: Impact of Endoscopic Training on Clinical Care

The management of clival chordoma in our group shifted around 2013 to mostly endoscopic, and proton beam was introduced for our multidisciplinary team. Consecutive patients who had surgical resection from 1987 to 2021 were reviewed. A total of 58 patients (39 patients after 2013) were analyzed. The...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-10, Vol.14 (20), p.5104
Main Authors: Hong, Sukwoo, Laack, Nadia, Mahajan, Anita, O'Brien, Erin K, Stokken, Janalee K, Janus, Jeffrey R, Choby, Garret, Van Gompel, Jamie J
Format: Article
Language:English
Subjects:
Biopsy
Care and treatment
Carotid arteries
Cerebrospinal fluid
Chi-square test
Cranial nerves
Diagnosis
Endoscopy
Magnetic resonance imaging
Medical personnel
Morbidity
Multidisciplinary teams
Multivariate analysis
Patients
Radiation therapy
Radiosurgery
Sinuses
Skull
Surgery
Surgical outcomes
Survival
Training
Tumors
Tumors, Embryonal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The management of clival chordoma in our group shifted around 2013 to mostly endoscopic, and proton beam was introduced for our multidisciplinary team. Consecutive patients who had surgical resection from 1987 to 2021 were reviewed. A total of 58 patients (39 patients after 2013) were analyzed. The mean tumor size was 3.7 cm, and the most common location was the upper clivus (43%). Compared to before 2013, after 2013, the endoscopic endonasal approach was more common (90%, p < 0.001), and more gross or near total resections (64%, p = 0.002) were attained. Ten cases (17%) were revision surgeries referred from elsewhere, and three cases (5%) underwent additional surgery elsewhere before adjuvant radiation. The postoperative cerebrospinal fluid leak occurred in 7%. Post-operative new cranial nerve deficits occurred in 32% before 2013, compared to 2.6% after 2013 (p = 0.004). For cases before 2013, 10 patients (53%) recurred during the median follow-up of 144 months (mean, 142 months), whereas for cases after 2013, seven patients (18%) recurred with a median follow-up of 35 months (mean, 42 months). 5-year progression-free survival was 58%, and 5-year overall survival was 87%. A specialized multidisciplinary team improved the resection rate compared to a historical cohort with an excellent morbidity profile.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14205104